Enliven Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELVN research report →
Range $65 – $82
Price Chart
About the company
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia.
- CEO
- Richard A. Fair
- IPO
- 2020
- Employees
- 61
- HQ
- Boulder, CO, US
Get TickerSpark's AI analysis on ELVN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.21B
- P/E
- -35.93
- PEG
- -1.81
- P/S
- 0.00
- P/B
- 4.36
- EV/EBITDA
- -38.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -18.55%
- ROIC
- -13.88%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-263,000+0.0%
- Op Income
- $-119,658,000
- Net Income
- $-103,694,000-16.5%
- EPS
- $-1.83+3.2%
- OCF Growth
- +3.9%
- FCF Growth
- +3.8%
- 52W High
- $62.32
- 52W Low
- $14.79
- 50D MA
- $51.91
- 200D MA
- $35.26
- Beta
- 0.24
- RSI (14)
- 61
- Avg Volume
- 1.42M
No earnings-call transcripts are available for ELVN yet.
- Free Float
- 63.8%
- Shares Outstanding
- 71.44M
- Float Shares
- 45.61M
of shares held by institutions
180 13F filers
Buy/sell ratio 0.29. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 10.03M | ▲ 3.20M |
| Orbimed Advisors LLC | 6.78M | ▼ 1.18M |
| Polar Capital Holdings PLC | 6.43M | ▲ 1.36M |
| Blackrock, Inc. | 4.36M | ▲ 675.00K |
| Vestal Point Capital, LP | 4.00M | ▲ 750.00K |
| Commodore Capital LP | 3.27M | 0 |
| Price T Rowe Associates Inc | 2.90M | ▲ 2.81M |
| Vanguard Group Inc | 2.80M | ▲ 248.65K |
| Vanguard Capital Management LLC | 2.57M | ▲ 400.84K |
| Citadel Advisors LLC | 2.07M | ▲ 325.08K |
| Fairmount Funds Management LLC | 1.86M | 0 |
| Siren, L.L.C. | 1.77M | ▲ 1.03M |
Held by 211 ETFs
Biggest fund positions in ELVN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 26 | Hohl Benjamin | sell | 4,630 |
| Aug 17, 26 | Hohl Benjamin | sell | 1,388 |
| Aug 17, 26 | Collins Helen Louise | other | 5,000 |
| Aug 17, 26 | Collins Helen Louise | other | 5,000 |
| Aug 17, 26 | Collins Helen Louise | sell | 3,900 |
| Aug 17, 26 | Collins Helen Louise | sell | 1,100 |
| Aug 4, 26 | Derynck Mika K | other | 20,491 |
| Aug 4, 26 | Derynck Mika K | other | 23,364 |
| Aug 4, 26 | Derynck Mika K | other | 27,567 |
| Aug 4, 26 | Derynck Mika K | other | 87,373 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ELVN coverage
Recent articles, reports, and earnings notes.
No research on ELVN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ELVN report →Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
benzinga.com · Aug 18
Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVN
defenseworld.net · Aug 6
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
prnewswire.com · Aug 5
Enliven Therapeutics, Inc. $ELVN is Avidity Partners Management LP’s 6th Largest Position
defenseworld.net · Aug 1
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
fool.com · Jun 27
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
fool.com · Jun 27
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
prnewswire.com · Jun 15
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
gurufocus.com · Jun 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.